162 related articles for article (PubMed ID: 30334503)
1. The GAIN Act legislation to combat antimicrobial resistance: Where do we stand?
Sfeir MM
Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1499-1500. PubMed ID: 30334503
[No Abstract] [Full Text] [Related]
2. Is the GAIN Act a turning point in new antibiotic discovery?
Brown ED
Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
[TBL] [Abstract][Full Text] [Related]
3. 2013 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
[No Abstract] [Full Text] [Related]
4. Raising the bar for market authorisation of new drugs.
Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
[No Abstract] [Full Text] [Related]
5. Examining Manufacturing Readiness for Breakthrough Drug Development.
Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
[No Abstract] [Full Text] [Related]
6. The FDA's critical path initiative: a brief introduction.
Coons SJ
Clin Ther; 2009 Nov; 31(11):2572-3. PubMed ID: 20110002
[No Abstract] [Full Text] [Related]
7. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
8. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
9. A three-step plan for antibiotics.
Nature; 2014 May; 509(7502):533. PubMed ID: 24877183
[No Abstract] [Full Text] [Related]
10. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
11. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
Lee R
J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994
[No Abstract] [Full Text] [Related]
12. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Zelenay JL
Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
[No Abstract] [Full Text] [Related]
13. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
Miller KL; Lanthier M
Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
[No Abstract] [Full Text] [Related]
14. Health, Wealth, and the 21st Century Cures Act.
Lo AW; Philipson TJ; von Eschenbach AC
JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
[No Abstract] [Full Text] [Related]
15. Industry and regulatory performance in 2012: a year in review.
Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
[TBL] [Abstract][Full Text] [Related]
16. Regulatory watch: impact of PDUFA on regulatory decision-making.
Hay M
Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755
[No Abstract] [Full Text] [Related]
17. GAIN Act legislation: is it enough?
Tillotson GS
Lancet Infect Dis; 2012 Nov; 12(11):823-4. PubMed ID: 23099071
[No Abstract] [Full Text] [Related]
18. Medicine. Can intellectual property save drug development?
FitzGerald GA
Science; 2012 Oct; 338(6106):483-4. PubMed ID: 23112323
[No Abstract] [Full Text] [Related]
19. Incentives for drug development--the curious case of colchicine.
Kesselheim AS; Solomon DH
N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
[No Abstract] [Full Text] [Related]
20. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
